Cargando…
Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients
Background: We aimed to investigate the effect of non-alcoholic fatty liver disease (NAFLD) on BNT162b2 immunogenicity against wild-type SARS-CoV-2 and variants and infection outcome, as data are lacking. Methods: Recipients of two doses of BNT162b2 were prospectively recruited. Outcomes of interest...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054100/ https://www.ncbi.nlm.nih.gov/pubmed/36992081 http://dx.doi.org/10.3390/vaccines11030497 |
_version_ | 1785015574265331712 |
---|---|
author | Cheung, Ka Shing Lam, Lok Ka Mao, Xianhua Tan, Jing Tong Ooi, Poh Hwa Zhang, Ruiqi Chan, Kwok Hung Hung, Ivan F. N. Seto, Wai Kay Yuen, Man Fung |
author_facet | Cheung, Ka Shing Lam, Lok Ka Mao, Xianhua Tan, Jing Tong Ooi, Poh Hwa Zhang, Ruiqi Chan, Kwok Hung Hung, Ivan F. N. Seto, Wai Kay Yuen, Man Fung |
author_sort | Cheung, Ka Shing |
collection | PubMed |
description | Background: We aimed to investigate the effect of non-alcoholic fatty liver disease (NAFLD) on BNT162b2 immunogenicity against wild-type SARS-CoV-2 and variants and infection outcome, as data are lacking. Methods: Recipients of two doses of BNT162b2 were prospectively recruited. Outcomes of interest were seroconversion of neutralizing antibody by live virus microneutralization (vMN) to SARS-CoV-2 strains (wild-type, delta and omicron variants) at day 21, 56 and 180 after first dose. Exposure of interest was moderate-to-severe NAFLD (controlled attenuation parameter ≥ 268 dB/M on transient elastography). We calculated adjusted odds ratio (aOR) of infection with NAFLD by adjusting for age, sex, overweight/obesity, diabetes and antibiotic use. Results: Of 259 BNT162b2 recipients (90 (34.7%) male; median age: 50.8 years (IQR: 43.6–57.8)), 68 (26.3%) had NAFLD. For wild type, there was no difference in seroconversion rate between NAFLD and control groups at day 21 (72.1% vs. 77.0%; p = 0.42), day 56 (100% vs. 100%) and day 180 (100% and 97.2%; p = 0.22), respectively. For the delta variant, there was no difference also at day 21 (25.0% vs. 29.5%; p = 0.70), day 56 (100% vs. 98.4%; p = 0.57) and day 180 (89.5% vs. 93.3%; p = 0.58), respectively. For the omicron variant, none achieved seroconversion at day 21 and 180. At day 56, there was no difference in seroconversion rate (15.0% vs. 18.0%; p = 0.76). NAFLD was not an independent risk factor of infection (aOR: 1.50; 95% CI: 0.68–3.24). Conclusions: NAFLD patients receiving two doses of BNT162b2 had good immunogenicity to wild-type SARS-CoV-2 and the delta variant but not the omicron variant, and they were not at higher risk of infection compared with controls. |
format | Online Article Text |
id | pubmed-10054100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100541002023-03-30 Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients Cheung, Ka Shing Lam, Lok Ka Mao, Xianhua Tan, Jing Tong Ooi, Poh Hwa Zhang, Ruiqi Chan, Kwok Hung Hung, Ivan F. N. Seto, Wai Kay Yuen, Man Fung Vaccines (Basel) Article Background: We aimed to investigate the effect of non-alcoholic fatty liver disease (NAFLD) on BNT162b2 immunogenicity against wild-type SARS-CoV-2 and variants and infection outcome, as data are lacking. Methods: Recipients of two doses of BNT162b2 were prospectively recruited. Outcomes of interest were seroconversion of neutralizing antibody by live virus microneutralization (vMN) to SARS-CoV-2 strains (wild-type, delta and omicron variants) at day 21, 56 and 180 after first dose. Exposure of interest was moderate-to-severe NAFLD (controlled attenuation parameter ≥ 268 dB/M on transient elastography). We calculated adjusted odds ratio (aOR) of infection with NAFLD by adjusting for age, sex, overweight/obesity, diabetes and antibiotic use. Results: Of 259 BNT162b2 recipients (90 (34.7%) male; median age: 50.8 years (IQR: 43.6–57.8)), 68 (26.3%) had NAFLD. For wild type, there was no difference in seroconversion rate between NAFLD and control groups at day 21 (72.1% vs. 77.0%; p = 0.42), day 56 (100% vs. 100%) and day 180 (100% and 97.2%; p = 0.22), respectively. For the delta variant, there was no difference also at day 21 (25.0% vs. 29.5%; p = 0.70), day 56 (100% vs. 98.4%; p = 0.57) and day 180 (89.5% vs. 93.3%; p = 0.58), respectively. For the omicron variant, none achieved seroconversion at day 21 and 180. At day 56, there was no difference in seroconversion rate (15.0% vs. 18.0%; p = 0.76). NAFLD was not an independent risk factor of infection (aOR: 1.50; 95% CI: 0.68–3.24). Conclusions: NAFLD patients receiving two doses of BNT162b2 had good immunogenicity to wild-type SARS-CoV-2 and the delta variant but not the omicron variant, and they were not at higher risk of infection compared with controls. MDPI 2023-02-21 /pmc/articles/PMC10054100/ /pubmed/36992081 http://dx.doi.org/10.3390/vaccines11030497 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cheung, Ka Shing Lam, Lok Ka Mao, Xianhua Tan, Jing Tong Ooi, Poh Hwa Zhang, Ruiqi Chan, Kwok Hung Hung, Ivan F. N. Seto, Wai Kay Yuen, Man Fung Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients |
title | Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients |
title_full | Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients |
title_fullStr | Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients |
title_full_unstemmed | Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients |
title_short | Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients |
title_sort | effect of moderate to severe hepatic steatosis on vaccine immunogenicity against wild-type and mutant virus and covid-19 infection among bnt162b2 recipients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054100/ https://www.ncbi.nlm.nih.gov/pubmed/36992081 http://dx.doi.org/10.3390/vaccines11030497 |
work_keys_str_mv | AT cheungkashing effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT lamlokka effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT maoxianhua effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT tanjingtong effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT ooipohhwa effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT zhangruiqi effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT chankwokhung effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT hungivanfn effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT setowaikay effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients AT yuenmanfung effectofmoderatetoseverehepaticsteatosisonvaccineimmunogenicityagainstwildtypeandmutantvirusandcovid19infectionamongbnt162b2recipients |